1. Scrip
  2. >>R&D
  3. >>Clinical Trials

SOLO-1 Lynparza Data In First-Line Ovarian Cancer Seen Boosting AstraZeneca's PARP Edge

 
• By Sten Stovall

In SOLO-1 Lynparza becomes the first PARP to show benefit in first-line BRCA-mutated ovarian cancer.

Ovarian cancer
Lynparza tablets showed statistically significant, clinically meaningful improvement in PFS vs placebo • Source: Shutterstock

Prospects for PARP inhibitor Lynparza (olaparib) were boosted when AstraZeneca PLC and partner Merck & Co. Inc. reported positive top-line results from the pivotal SOLO-1 trial testing the tablet as a first-line maintenance monotherapy in patients with BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.

In the Phase III SOLO-1 study Lynparza showed "statistically significant and clinically meaningful improvement" in progression-free survival (PFS) versus placebo. The safety and tolerability profile of Lynparza was consistent with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.